Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms

P. Dubé, L. Sideris, C. Law, L. Mack, E. Haase, C. Giacomantonio, A. Govindarajan, M.K. Krzyzanowska, P. Major, Y. McConnell, W. Temple, R. Younan, J.A. McCart


To meet the needs of patients, Canadian surgical and medical oncology leaders in the treatment of peritoneal surface malignancies (psms), together with patient representatives, formed the Canadian HIPEC Collaborative Group (chicg). The group is dedicated to standardizing and improving the treatment of psm in Canada so that access to treatment and, ultimately, the prognosis of Canadian patients with psm are improved.

Patients with resectable psm arising from colorectal or appendiceal neoplasms should be reviewed by a multidisciplinary team including surgeons and medical oncologists with experience in treating patients with psm. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be offered to appropriately selected patients and performed at experienced centres.

The aim of this publication is to present guidelines that we recommend be applied across the country for the treatment of psm.


peritoneal surface malignancy; pseudomyxoma peritonei; carcinomatosis; colorectal cancer; appendiceal cancer; hyperthermic intraperitoneal chemotherapy; cytoreductive surgery; peritoneal metastasis

Full Text:



Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)